Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in locally advanced colon cancer
NCT04123925Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in colon cancer, sponsored by National Cancer Institute. Primary endpoints: Tolerability and Safety at 5 weeks, Clinical Activity and 1 more. Started Jun 2018; status: completed.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04123925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123925.